Share on StockTwits

Alnylam Pharmaceuticals (NASDAQ:ALNY) SVP Laurence Reid sold 13,500 shares of Alnylam Pharmaceuticals stock on the open market in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $67.34, for a total transaction of $909,090.00. Following the completion of the transaction, the senior vice president now directly owns 3,905 shares of the company’s stock, valued at approximately $262,963. The sale was disclosed in a filing with the SEC, which is available at this link.

Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 1.06% on Wednesday, hitting $67.33. 487,580 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 1-year low of $47.03 and a 1-year high of $112.57. The stock has a 50-day moving average of $58.53 and a 200-day moving average of $64.17. The company’s market cap is $5.141 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings data on Thursday, August 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.07. The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $9.36 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was down 16.0% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals will post $-5.37 earnings per share for the current fiscal year.

A number of research firms have recently commented on ALNY. Analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, August 14th. They now have a $69.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus price target of $84.50.

Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.